Pharmaceuticals
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...
Future Health highlights greater access to treatment for Mental Health Month
SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- A recent poll
Samsung Biologics Reports First Quarter 2024 Financial Results
* Recorded Q1'24 consolidated revenue of KRW 946.9 billion * Recorded Q1'24 consolidated operating profit of KRW 221.3 billion * Sustained growth driven by ongoing strategic expansion in capacity and portfolio INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 20794...
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO:Jae...
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech firm with a pipeline of immuno-oncology drug candidates, to share technology and clinical ...
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
SAN DIEGO and WUHAN, China, April 23, 2024 /PRNewswire/ -- HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the N...
Brise Pharmaceuticals Raises nearly $20M in Series Pre-A and Pre-A+ Financing
SHANGHAI, April 22, 2024 /PRNewswire/ -- Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately$20 million. This Pre-A round is led by Shunxi F...
PharmAbcine's U.S. Subsidiary, Wincal Biopharm, to Present Preclinical Data from its Proprietary OPC Platform Targeting Ocular Diseases at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
* Preclinical data from the next generation eyedrop platform to be unveiled for the first time at ARVO 2024 DAEJEON, South Korea, April 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therap...
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD)....
GT20029 China Phase II Trial For AGA Reached Primary Endpoint
SUZHOU, China, April 21, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced thatthe China phase II clinical trial (the "Phase II Clinical Trial") of i...
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards
SINGAPORE, April 18, 2024 /PRNewswire/ -- Juniper Biologics
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a mult...
TaiGen Successfully Completes TG-1000 Phase III Study
TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is...
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr.Dong Liu and Chief Scientific Officer Dr.Shaojiang Deng, announced a resolution of their recent dispute wit...
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
SHANGHAI, April 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) An...
Pre-clinical result of LP-005, a novel bi-functional complement antibody-fusion protein was unveiled by LongBio at WCN2024
BUENOS AIRES, Argentina, April 15, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare dise...
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90% SYDNE...
【2024 AACR Late Breaking Research】TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations
NANJING, China and GAITHURSBURG, Md., April 12, 2024 /PRNewswire/ -- TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to disc...
Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer
SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. John Lee, MD, PhD, as its Chief Medical Office...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 292 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 290 media titles]
2024-04-22 06:00With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00